Management reshuffle at Affimed
This article was originally published in Scrip
Affimed Therapeutics, a therapeutic antibody company, has reorganised its management team under the leadership of Dr Adi Hoess, now CEO, and Dr Rolf Guenther, now COO. Dr Hoess was previously the company's chief commercial officer, while Dr Guenther was previously CEO. The company believes this reorganisation will support its new strategy to drive its projects into later stage development.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.